IP Law News

U.S. Drugmakers Face New Intellectual Property Hurdles in China

Sept. 16, 2019, 8:20 AM

The U.S. pharmaceutical industry wants a piece of China’s market of 1.4 billion people, but protecting its intellectual property remains a challenge, despite sweeping new changes in Chinese law.

China’s passage of multiple IP laws since 2018 has coincided with the trade war and pressure from the Trump administration for China to address IP theft and its purportedly weak IP protections. Meanwhile, China is working toward dominance in the global drug market, a stated goal of in “Made in China 2025,” an industrial policy to make the nation a leader in international high-tech manufacturing.

Describing the changes in April, Chinese...

To read the full article log in. To learn more about a subscription click here.